Use of Topotecan in Patients With Refractory Acute Leukemia

US Department of Veterans Affairs (VA)

Status and phase: Completed; Phase 2

Conditions: Non-Hodgkin's Lymphoma; Leukemia

Treatments: Drug: Etoposide; Drug: Topotecan; Drug: Mitozantrone

Study type: Interventional

Funder types: Other U.S. Federal agency; Industry

Identifiers

NCT00100477

CADE-RCD1

Details and patient eligibility

About

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).

Full description

The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).

Enrollment: 10 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients in the following disease categories will be considered eligible for this study:

• Any acute leukemia beyond an initial attempt to induce a remission or after relapse
• Chronic Myelogenous Leukemia in Blast Phase
• Refractory Multiple Myeloma
• Refractory non-Hodgkin's and Hodgkin's Lymphoma
• Patients must be more than 14 days beyond prior myelotoxic chemotherapy
• Several other eligibility criteria apply.

Exclusion criteria

• None

Trial design

10 participants in 1 patient group

Arm 1

Other group

Treatment:

Drug: Topotecan

Drug: Mitozantrone

Drug: Etoposide